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Abstract 
Introduction: Consumption of blood products 
is significant aiming to treat low cell counts and 
improve quality of life however 9% to 44% of the 
total consumption in centres abroad are unjustified. 
We reviewed thresholds at which blood products 
were administered and costs incurred by 
administering blood products at the local paediatric 
oncology ward at Mater Dei hospital and assessed 
whether they were inkeeping with local guidelines. 
Methods: Patient files were analyzed 
retrospectively for demographics, disease, type and 
amount of blood products used from January to 
May 2013. The costs involved were obtained from 
the Blood Bank at Mater Dei Hospital. The 
standards used were the protocol by HBB 
regarding administration on KURA and ‘Supportive 
care protocols’ in paediatric oncology and 
haematology.  
Results: Nine children were given blood 
products. Red cell products (RCP) use ranged from 
0-10 units. and platelets derived products ranged 0-
12 units per patient. haemoglobin levels and
platelet counts before transfusions ranged from 3.1
to 8.6g/dL and 9 to 60x109/L respectively. The
total cost for the department was €17,950 while the
total amount spent for tests done prior to ordering
products was €3,276 out of 22 RCP requests for
transfusion only once were RCPs transfused above
the standard 7g/dL. Platelets were requested 26
times. Documentation regarding the reason for
administration was lacking in patient files.
Conclusion: The use of blood products is 
dependent on patient needs and is not influenced by 
prices. Thresholds at which platelets and RCP are 
admnistered vary according to the clinical scenario. 
Rising costs and shrinking donor pools require 
blood products to be used judiciously. 
Introduction 
Malta has offered blood product transfusion 
services since the nineteen thirties, then at the 
Central Civil Hospital. New premises for the 
Donation Area of the National Blood transfusion 
Service (NBTS), opened in 2007, are now available 
for people to donate blood.1 Despite the 
consumption of blood products being significant 
costs for unjustified blood transfusion account from 
9% to 44% in centers abroad.2 
Transfusions provide a treatment and improve 
the quality of life for patients suffering from 
chronic diseases.3 Alternatives to transfusions may 
prove to have adverse or suboptimal effects making 
transfusions best practice in anaemia, 
thrombocytopenia, and in the context of a 
haematological malignancy. In these situations, 
specialised blood products may also be required.4  
In 2000/1 the UK average cost of blood products 
(adult red blood cells, adult fresh frozen plasma, 
adult platelet concentrate, adult cryoprecipitate, 
paediatric products) had a 256% increase compared 
to 1994/5. This cost is burdened by a shrinking 
donor pool, an ageing population and more 
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Attempts at comparing the complete cost of 
blood transfusions by centres has been difficult. 
Costs are usually compared between red cell 
products (RCP) as these are the commonest units 
used. Intangible costs for the centre and society are 
also generally not included.8
What are the current available alternatives to 
blood transfusions? “Supportive Care protocols of 
Paediatric Haematology and Oncology” provide 
guidelines on the management of blood products at 
Rainbow ward.9 From them local guidelines have 
been established, namely the ‘Guideline on 
administration of blood components’.10 
Cytomegalovirus (CMV)-negative (–ve) platelets 
are used in newly diagnosed leukemics until CMV 
status is known, or CMV negative recipients. 
Apheresis platelets arise from a single donor and 
are preferred from pooled platelets as they reduce 
the exposure to multiple donors preventing future 
transfusion reactions due to alloimmunisation. 
Irradiated RCP are used in recipients with 
allogeneic bone marrow, peripheral blood stem cell 
transplants or harvesting, Hodgkin’s disease etc. 
Graft-versus-host disease is therefore prevented by 
inactivating lymphocytes in donor components.10  
Aims 
To research the amount, cost and cell indices 
at which blood products are used in Rainbow Ward 
at Mater Dei Hospital, between the months of 
January and May 2013 including: 
 red cell products,
 CMV-ve red cell products,
 pooled platelets,
 irradiated pooled platelets,
 apheresis platelets.
 irradiated apheresis platelets
Method 
Authorization from the Data Protection Officer 
at Mater Dei Hospital was obtained to review the 
files of patients admitted to Rainbow ward between 
the months of January to May 2013. Patient files 
were analysed retrospectively for:  
 age,
 gender,
 disease,
 type and amount of blood products used.
Exclusion criteria included: 
 patients transfused outside Rainbow ward,
 patients who were above 16 years of age,
 patients receiving transfusions outside the set
time frame.
The cost of each blood product was obtained
from the blood bank at Mater Dei Hospital. Blood 
products used in this study were divided into: 
RCPs, CMV-ve RCPs, pooled platelets, irradiated 
pooled platelets, apheresis platelets and irradiated 
apheresis platelets. The currency used was the euro. 
Patient details were anonymised.  
Results 
Nine children were transfused between 
January and May 2013, with a range of 0-10 units 
of RCPs and 0-12 therapeutic doses/units of 
platelets. The total amount spent for tests used to 
order blood products was that of 3276 euro, as 
provided by the Blood Bank at Mater Dei Hospital. 
47 units of RCP and 30 platelet blood products 
were used in all (Figure 1). The haemoglobin range 
before transfusing RCP ranged from 3.1-8.6g/dl. 
RCP transfusions occurred 22 times, with only one 
instance where RCP were transfused above 8g/dl. 
RCP was the commonest blood product used 
whereas irradiated platelets were the least used 
(Figure1).  
Figure 1: Number of units used according to blood 
product 
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Platelet counts before transfusion ranged 
from 9-60x109/liter.  Platelets were transfused on 26 
occasions, with eleven instances of platelet indices 
above 20x109/L. 
The total cost over the five month period for 
the department was 17,950 euro. The greatest cost 
per condition was for acute lymphoblastic 
leukaemia (ALL)-1 – 5375 euro whilst the lowest 
cost was for ALL-4 at 125 euro. Patients’ duration 
of treatment ranged from weeks to months. 
ALL was the commonest condition treated, 
accounting for four out of nine patients. It was also 
the most costly per patient due to more frequent use 
of apheresis platelets (Table 2).  
Table 1: Data regarding patients and products 
Number of patients 9 
Age Range 2-13 years
Mean Age 4 years 8 months 
Total Units of RCPs 47 
Range of RCP used 0-10 units
Total price of RCPs 5750 euro 
Total number of platelet products used 30 units 
Range of platelet products used 0-12 units
Total price of platelet products 12200 euro 
Range of total cost per patient 125-5375 euro
Mean total cost per patient 1994 euro 
Range of haemoglobin on transfusing RCP 3.1-8.6g/dl 
Range of platelet count on transfusing platelets 9-60x109/l
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Table 2: Amount spent on blood products per patient 
Condition treated Cost per blood product (euro) 
RCP CMV -ve
red cells 
Apheresis 
platelets 
Pooled 
platelets 
Pooled 
platelets 
irradiated 
Irradiated 
apheresis 
platelets 
Total 
amount 
spent 
ALL-1 1250 125 3500 500 0 0 5375 
ALL-2 625 0 0 250 250 0 1125 
ALL-3 375 0 0 0 0 0 375 
ALL-4 125 0 0 0 0 0 125 
Aplastic anaemia 375 0 1400 250 0 0 2025 
Burkitt's lymphoma 250 0 0 250 0 0 500 
Nephroblastomatosis 1125 0 2100 1000 0 0 4225 
Retinoblastoma 0 0 0 250 0 0 250 
Yolk sac carcinoma 1500 0 700 1750 0 0 3950 
Total product used 5625 125 7700 4250 250 0 17950 
Table 3: Prices for blood products before and after 2015 in Malta11 
Blood product Prices according to year (euro) 
2006-2014 2015 
Red cell concentrate 125.00 166.10 
Pooled platelets 250.00 346.27 
Single donor platelets 700.00 714.90 
Fresh frozen plasma 70.00 119.78 
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Limitations 
1. It was unclear at times whether the products
requested were actually used due to missing
documentation in patient files.
2. The indication for blood product 
administration was not included. 
3. Cycles of chemotherapy and radiotherapy
were not noted.
4. Protocol by HBB regarding administration
on KURA on administration of blood
products specifically for paediatric patients
were set up by the haematology working
group at Mater Dei Hospital.10
5. Documentation of transfusion having
occurred was not documented at times
Discussion 
95% of red cell transfusions (n=21) were 
performed with a hemoglobin of less than 8mg/dl. 
Supportive care protocols recommend transfusions 
occurring at thresholds of 7mg/dl but patients who 
are symptomatic, suffering from aplastic anemia or 
bone marrow failure syndromes have higher 
thresholds.11 
43% (n=13) of platelet transfusions occurred 
at levels above 20 x109/l. Protocols recommend 
routine transfusion occurring at levels less than 10 
x109/l and less than 20 x109/l if suffering concurrent 
illness/bleeding/on anticoagulants. However prior 
to a potentially hemorrhagic event such as a lumbar 
puncture or change of central line platelet 
transfusions are recommended if levels are less than 
50 x109/l. 11 
Over five months 17,950 euro was spent on 
blood products with an average cost of almost 2000 
euro per patient. 
Included also was the total cost of the 
process used to choose blood products for patients. 
The first process involves “Type and Screen” 
(T&S). This step checks blood group and antibody 
detection. If no antibodies are present, compatibility 
testing is performed by a "Spin and Read" (S&R), 
which is carried out at room temperature. If the 
samples indicate an antibody is present 
compatibility testing is performed by an IAT cross-
match. If the S&R or IAT cross match is negative 
the blood product can then be issued. T&S are 
performed on each unit of RCP requested, whereas 
S&R or IAT crossmatch are performed on RCP that 
are issued but not necessarily transfused. 3276 euro 
were spent on these processes.13 On average almost 
2000 euro was spent per patient in the five month 
period (Table 1).  
Prices for blood products have remained 
stable in Malta from the year 2006 to 2014. These 
prices were changed owing to increasing costs in 
the production of blood products11. This rise reflects 
the rise in costs shown in other countries however it 
does not account for other costs such as hospital 
care, nursing etc. 
Conclusion 
The use of blood products is dependent on 
patient needs and is not influenced by prices. 
Thresholds at which platelets and RCP are 
admnistered vary according to the clinical scenario. 
In view of rising costs and shrinking donor pools 
these resources should be used judiciously. Better 
documentation would ascertain whether platelet 
products were used adequately. 
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